linjc16/ctgov huggingface dataset:
Physical Activity and the Risk of COVID-19 Infection and Mortality

Study Overview
=================
Brief Summary
-----------------
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently, there is no cure for COVID-19, except for supportive treatments. Quarantine for a defined period is the best option to reduce the spread of COVID-19. Physical activity has been shown to reduce the risk of serious community-acquired infections. However, it remains unanswered is whether physical activity has protective effects against SARS-CoV-2 infection and COVID-19 related mortality. This study aimed to examine the association of PA with the morbidity and mortality of COVID-19 infection in the entire South Korean population.

Official Title
-----------------
Physical Activity and the Risk of COVID-19 Infection and Mortality

Conditions
-----------------
Covid19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all Koreans who tested positive for SARS-CoV-2 more than 18 years old who underwent public health screening between 2014 and 2017 Exclusion Criteria: missing values about physical activity

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SARS-CoV-2 positivity rate (%) | The SARS-CoV-2 infection was confirmed using the real-time reverse transcriptase polymerase chain reaction of pharyngeal and nasal swab samples, in accordance with the WHO recommendations | 7 years | 
| COVID-19 related mortality rate (%) | The COVID-19 related mortality was defined as the termination of isolation due to death. | 7 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Physical activity
Life Style Modification Medical and Surgical Management in Patients With Obesity

Study Overview
=================
Brief Summary
-----------------
In this is an observational study, obese patients that administed and followed in endocrinology clinic of Marmara University Medical school hospital will follow for clinical and laboratory parameters prospectively for 5 years

Detailed Description
-----------------
Following available clinical and laboratory parameters will be collected for 5 years Treatment modalities ( life stye modification, medication, bariatric surgery) eating habits quality of life body mass index , blood pressure body fat distribution (impedance measurement) laboratory parameters (serum glucose, OGTT, insülin, lipids,creatinin ,ALT AST,CBC, ferritin calcium, phosphate, Parathormone,25 OH vitamin D, vitamin B12 ,uric acid, albumin, FSH LH testosteron, estrogen ) muscle strength (dynomometer measurement) skin glikolization autoflouresent measurement Bone mineral density mesurements (femur, spine ,forarm)

Official Title
-----------------
Evaluation of Life Style Modification Medical and Surgical Treatment Modalities in Patients With Obesity: An Observational Study

Conditions
-----------------
Obesity, Weight Change, Body, Obesity; Endocrine, Obesity, Metabolically Benign

Intervention / Treatment
-----------------
* Procedure: bariatric surgey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Body mass index over 30 kg/m2 age between 18-65 years Exclusion Criteria: active malignancy pregnancy during involvement period chronic inflamatuar diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| life syte modification only<br>obese patients followed with life style modification | Procedure: bariatric surgey<br>* patients undergone bariatric surgery or prescribed antiobesity drugs<br>* Other names: antiobesity drugs ,liraglutide or orlistat;|
| medical teatment with antiobesity drugs<br>patients prescribed antiobesity drugs | Procedure: bariatric surgey<br>* patients undergone bariatric surgery or prescribed antiobesity drugs<br>* Other names: antiobesity drugs ,liraglutide or orlistat;|
| bariatric surgery<br>patients undergone bariatric surgery | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| weight loss | %5-10 weight loss | 6 months interval | 
| metabolic improvement | blood glucose | 6 months interval | 
| metabolic improvement | serum lipid levels | 6 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
obesity, weight loss
TB Immunotherapy Trial With Heat-killed M. Vaccae

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to carry out multi-country (Ukraine and Mongolia), placebo-controlled, randomized Phase III trial in patients with drug-sensitive, multi-drug resistant (MDR-TB) and TB-HIV and identify efficacy and safety of whole-cell, heat-killed Mycobacterium vaccae formulated as a pill (V7) and consequently conduct confirmatory trials in intended registration countries, such as China, Russia and South Africa, etc.

Detailed Description
-----------------
Main end-point is negative sputum conversion rate after one month in patients on V7 vs placebo arm, both arms will receive conventional anti-tuberculosis chemotherapy consisting of 1st and/or 2nd line TB drugs according to baseline diagnosis

Official Title
-----------------
Phase III and Dose Ranging Trial of Heat-killed M. Vaccae (V7)

Conditions
-----------------
Tuberculosis

Intervention / Treatment
-----------------
* Biological: V7
* Biological: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: confirmed diagnosis of TB sputum smear positive Exclusion Criteria: pregnant likely to be non-compliant due to drug and/or alcohol abuse mentally unfit to comply with treatment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: V7: Heat-inactivated M. vaccae pill<br>Daily pill of V7 together with standard tuberculosis therapy | Biological: V7<br>* One pill of V7 once daily for 30 days together with standard of care TB drugs<br>* Other names: V7 or tableted heat-inactivated mycobacterium vaccae;|
| Placebo Comparator: Placebo pill<br>one pill of placebo pill once per day together with standard of care TB drugs | Biological: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bacillary sputum smear clearance | blinded assessment of sputum clearance score | two years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| changes in body weight | comparison of body weight between treatment arm and placebo | 2 years | 
| changes in body mass index (BMI) | comparison of body mass index (BMI) between treatment arm and placebo | 2 years | 
| changes in inflammation markers | changes in erythrocyte sedimentation (ERS) rate and leukocyte counts | 2 years | 
| changes in liver function test | changes in ALT, AST and total bilirubin levels | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
M. vaccae, TB, MDR-TB, V7-immunitor
Investigation of Platelet Function and Aspirin Resistance in Chronic Dialysis Patient

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether aspirin resistance has impact on cardiovascular event in dialysis patient.

Detailed Description
-----------------
Dialysis patient inevitably suffered from uremic bleeding although improvement of dialysis care in the past decades. Physicians used to check bleeding time as a surrogate marker for uremic bleeding. However, bleeding time isn't accurate and as well known, is poorly correlated with clinical bleeding such as surgical bleeding. Platelet function assay (PFA) is a newly developed method to measure platelet aggregation in vitro and is validated in many sorts of platelet disorders. Recently, PFA was also used to evaluate aspirin responsiveness in patients who had taken aspirin. Our study is aim to investigate uremic thrombocytopathy via PFA of dialysis patient in Taiwan. Furthermore, we will study aspirin resistance in dialysis patient.

Official Title
-----------------
Investigation of Platelet Function and Aspirin Resistance in Chronic Dialysis Patient

Conditions
-----------------
End Stage Renal Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: dialysis >3 months Hb>10 g/dl & Plt > 10000 Exclusion Criteria: using medication which interfere PFA except aspirin terminal disease such as malignancy active vasculitis

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| aspirin responsive<br>PFA Col/EPI normal | |
| aspirin resistance<br>PFA Col/epi showed resistance | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cardiovascular event, bleeding event,and thrombosis |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
aspirin resistance, platelet function assay, dialysis, end stage renal disease
Metabolic Syndrome and Fingertip Endothelial Dysfunction

Study Overview
=================
Brief Summary
-----------------
Life-style intervention with dietetic and exercise therapy is an important fundamental approach to patients with metabolic syndrome (MetSyd) which may cause endothelial dysfunction leading to cardiovascular events. We investigated whether the life-style modification by dietetic and exercise instruction could improve endothelial dysfunction assessed by a new non-invasive and automatic device; digital reactive hyperemia peripheral arterial tonometry (RH-PAT).

Detailed Description
-----------------
Outline of methods RH-PAT was measured in high-risk patients under 70 years old. The MetSyd was defined according to guidelines of the National Cholesterol Education Program Third Adult Treatment Panel (NCEP - ATP III). We instructed all MetSyd patients about the dietetic and exercise therapy according to the Japan Atherosclerosis Society Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases. we conducted a questionnaire survey of the self-assessment for dietetic and exercise instruction program, respectively.

Official Title
-----------------
Achievement of Dietetic and Exercise Therapy Evaluated by Self-assessment Score Significantly Improved Endothelial Dysfunction in Patients With Metabolic Syndrome

Conditions
-----------------
Metabolic Syndrome

Intervention / Treatment
-----------------
* Other: Lifestyle instruction


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Under 70 years old and preserved left ventricular systolic function (left ventricular ejection fraction ≥ 50%) Exclusion Criteria: Severe valvular heart disease Atrial septal defect Myocarditis Cardiomyopathy Active inflammatory diseases Pulmonary hypertension Chronic kidney disease on hemodialysis Advanced hepatic disease Leukemia Schizophrenia; AND Cerebrovascular disease and residual hemiplegia.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Lifestyle instruction<br> | Other: Lifestyle instruction<br>* Instruction dietetic and exercise therapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Endothelial function assessed by RH-PAT |  | About 1 year later | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Metabolic status including waist circumference |  | About 1 year later |
Latent Tuberculosis Infection in Bone Marrow Transplant Recipients

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to estimate the usefulness of a T cell-based assay (i.e. Quantiferon-Gold In-Tube assay) for diagnosis of latent tuberculosis infection (LTBI) in bone marrow transplant recipients. For this purpose, the investigators enrolled bone marrow transplant recipients and observed the developement of tuberculosis after the transplantation.

Detailed Description
-----------------
All adult bone marrow transplant recipients admitted to Asan Medical Center will be enrolled. Quantiferon-Gold In-Tube assay will be performed. Isoniazid prophylaxis will be given only to patients with clinical risk factors (i.e. recent contact with active pulmonary TB patient or inadequate treatment history with abnormal CXR). However, isoniazid prophylaxis will be not given based on positive TST or positive Quantiferon-Gold In-Tube assay.

Official Title
-----------------
A Prospective Observational Study of Usefulness of a T Cell-based Assay for Latent Tuberculosis Infection in Hematopoietic Stem Cell Transplant Recipients

Conditions
-----------------
Tuberculosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 16 or more Bone marrow transplant recipients Exclusion Criteria: Recent contact of patients with active pulmonary tuberculosis Suspected active tuberculosis

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| QFT (+) vs QFT (-)<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| development of tuberculosis |  | after transplantation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| all cause mortality |  | after transplantation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
tuberculosis, bone marrow transplant, diagnosis
Cell Mediated Immunity and the Prediction of CMV Infection In Solid Organ Transplant Recipients

Study Overview
=================
Brief Summary
-----------------
Cytomegalovirus (CMV) is a common cause of illness in patients who have undergone a transplant. Serious infections due to CMV can affect many parts of the body including the lungs, the gut, and the liver. Since transplant recipients are at risk for CMV or have evidence of infection with CMV, they are given an antiviral drug (usually ganciclovir or valganciclovir). Despite this, there are a chance that CMV infection may cause problems in the future. The purpose of this study is to assess how well patients'immune systems responds to the CMV virus, so that in the future it may be possible to predict which patients are at highest risk of CMV.

Official Title
-----------------
Cell Mediated Immunity and the Prediction of CMV Infection In Solid Organ Transplant Recipients

Conditions
-----------------
Transplant

Intervention / Treatment
-----------------
* Procedure: Monitoring-blood samples drawn for CMV testing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female patients who fulfill the following criteria are eligible for inclusion. CMV D+/R- liver, kidney and heart recipient CMV R+ liver,kidney and heart recipients who have received thymoglobulin induction therapy. D+/R- and R+ lung transplant recipients. Able to give written informed consent Are willing and able to comply with the protocol Age >=18 years Exclusion Criteria: Patient unwilling or unable to give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Monitoring-blood samples drawn for CMV testing|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
liver transplant, lung transplant, kidney transplant, heart transplant, CMV CMI
Mid-term Survival and Quality of Life of Elderly Patients Undergoing Open Heart Surgery

Study Overview
=================
Brief Summary
-----------------
The purposes of the investigators study is to examine the overall survival and quality of life in elderly patients (> 75 years) undergoing open heart surgery at Hadassah medical center between 2008-2011. All alive patients will be phone interviewed using the 36-item short form health survey. Results will be compared to similar health survey results (36-SF)obtained from a group of Israeli adults who had no open heart surgery (controlled group). The investigators hypothesize that elderly patients achieve improvement in quality of life after open heart surgery with acceptable operative morbidity and mortality.

Official Title
-----------------
Mid -Term Survival and Quality of Life of Elderly Patients Undergoing Open Heart Surgery

Conditions
-----------------
Quality of Life

Intervention / Treatment
-----------------
* Other: No intervention in this study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all patients age > 75 years who discharged alive after surgery Exclusion Criteria: death

Ages Eligible for Study
-----------------
Minimum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients age >75 y who underwent open hear surgeary<br>The cohort study consist of all patients > 75 y, undergoing open heart surgery between 2008-2011 at Hadassah medical center. | Other: No intervention in this study<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life |  | 2-4 years |
Trial of a Botulinum A Toxin (Botox) Injection in the Gastrocnemius Muscle in Children With Idiopathic Toe Walking

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the effect of Botox and casting to placebo and casting for reducing toe walking problems in children who are idiopathic toe walkers.

Detailed Description
-----------------
Patients who have been seen by one of the 5 paediatric orthopaedic surgeons at British Columbia's Children's Hospital and have been referred to the Shriner's gait lab for assessment of idiopathic toe walking will be eligible for the study.

Official Title
-----------------
Randomized Controlled Trial of a Botulinum A Toxin (Botox) Injection in the Gastrocnemius Muscle in Children With Idiopathic Toe Walking

Conditions
-----------------
Idiopathic Toe Walking

Intervention / Treatment
-----------------
* Drug: Botox injections


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who have been seen by one of the 5 paediatric orthopaedic surgeons at British Columbia's Children's Hospital and have been referred to the Shriner's gait lab for assessment of idiopathic toe walking Clinical toe walkers - toe walkers as per gait lab's definition (loss of 1st ankle rocker, early heel rise [prior to 30% of the cycle] and A1 kinematic data) Aged 5 - 15 years old Parents and patients educated about protocol and willing to partake Cooperative patient with gait analysis and injection

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Botox injections|Data not known.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary outcome will be based on gait analysis data - specifically whether post injection gait analyses show a reduction in the features that were used to determine the severity of the subjects' toe walking problem. |  | Data not known | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ankle range of motion (dorsiflexion and plantarflexion) |  | collected at every visit | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Randomized control trial; placebo-control study